1.0 Subject and Purpose

This letter provides guidance related to newly amended rules in 26 Texas Administrative Code (TAC) Chapter 554, which become effective January 2, 2022. The newly amended rules implement House Bill 1848 and House Bill (HB) 2050 passed during the 86th Texas Legislative Session, 2019, Regular Session, and include additional requirements related to:

- consent to antipsychotic or neuroleptic medication (26 TAC §554.1207);
- rapid influenza diagnostic tests (26 TAC §554.1601(b)(4)); and
- monitoring of multidrug-resistant organisms (26 TAC §554.1601(b)(2)(A)).

The newly amended rules also amend requirements related to annual in-service training for nurse aides to include infection prevention and control training (26 TAC §554.1001).

This provider letter was updated to reflect the correct effective date of the rules, which is January 2, 2022.

2.0 Policy Details & Provider Responsibilities

2.1 Consent to Prescription of Antipsychotic or Neuroleptic Medication

For a resident, or a resident’s legally authorized representative, to provide consent to the prescription of an antipsychotic or neuroleptic medication, the consent must be documented on a form prescribed by
HHSC (consent form), which is Form 3713\(^1\). The Form 3713, either the original version or a copy, must be added to the resident's clinical record\(^2\).

All other requirements related to a resident’s consent to psychoactive medication still apply to antipsychotic and neuroleptic medication, including:

- A person may not administer a psychoactive medication to a resident unless the resident, or the resident’s legally authorized representative, has consented to the medication, or the resident is having a medication-related emergency;
- Consent must be given voluntarily and without coercive or undue influence; and
- The person prescribing the medication, that person’s designee, or the NF’s medical director provides the required information related to the medication to the resident or the resident’s legally authorized representative.

### 2.2 Rapid Influenza Diagnostic Tests

NFs must include in their infection prevention and control programs procedures for making rapid influenza diagnostic tests available to facility residents\(^3\). Facilities will have to determine the most appropriate method for ensuring rapid influenza diagnostic tests are available to residents. Facilities will not be required to store rapid influenza tests in the facility if there are other ways to ensure availability, such as partnering with local pharmacies, doctors’ offices, or laboratories. Facilities must also educate residents on the potential out-of-pocket costs related to rapid influenza diagnostic tests before the resident submits to a test.

### 2.3 Monitoring of Multidrug-Resistant Organisms

NFs must include in their infection prevention and control programs a system of surveillance designed to identify possible multidrug-resistant organisms\(^4\). “Multidrug-resistant organisms” (MDROs) refer to

---

1. [26 TAC §554.1207(c)(4)]
2. [26 TAC §554.1207(c)(5)(B)]
3. [26 TAC §554.1601(b)(4)]
4. [26 TAC §554.1601(b)(2)(A)]
microorganisms, predominantly bacteria, that are resistant to one or more classes of antimicrobial agents. Although the names of certain MDROs describe resistance to only one agent, these pathogens are frequently resistant to most available antimicrobial agents and include multidrug-resistant gram-negative bacteria, Carbapenem-resistant Enterobacteriaceae, and extended spectrum beta-lactamase-producing Enterobacteriaceae.

MDROs are a well-researched issue in healthcare settings and can be very harmful to residents. NFs are already required to have an antibiotic stewardship program that includes antibiotic use protocols and a system to monitor antibiotic use, which is to prevent MDRO outbreaks. The CDC recommends long-term care facilities identify experts who can provide consultation related to MDROs as needed. There are several resources related to the prevention and surveillance of MDROs, including:

- CDC: Multidrug-resistant organisms (MDRO) Management – this includes specific guidance for long-term care facilities
- DSHS: Antibiotic Resistance/Multidrug-Resistant Organisms Home – this includes links to various resources.
- Facilities can also send MDRO questions to MDROTexas@dshs.texas.gov

2.4 Annual In-Service Infection Prevention and Control Training

HHSC is requiring facilities to provide two-hours of infection control and personal protective equipment training as a part of the 12 hours of in-service training that must be provided to nurse aides each year. This requirement is in response to frequently found infection prevention and control noncompliance before and during the COVID-19 public health emergency.

Facilities can use the same methods for infection control and personal protective equipment training as used for other in-service training requirements. For example, staff training may be facilitated through any combination of in-person instruction, webinars or supervised

---

5 Definition from State Operations Manual, Appendix PP, Guidance for F880 – Infection Control
6 26 TAC §554.1001(a)(4)(G)(ii)
practical training hours. However, the effectiveness of the training must be sufficient to ensure that facility staff can demonstrate the necessary skills and competencies related to infection control and personal protective equipment.

3.0 Background/History

On January 2, 2022, the Health and Human Services Commission (HHSC) adopted new rules that amend requirements related to consent for the prescription of antipsychotic or neuroleptic medication, annual in-service trainings, and infection prevention and control programs. The new rules implement §§242.505(c-1)-(c-3), 81.014, and 81.015, Texas Health and Safety Code, as added by HB 2050 and HB 1848 of the 86th Legislature, Regular Session, 2019.

4.0 Resources

Form 3713

5.0 Contact Information

If you have any questions about this letter, please contact the Policy and Rules Section by email at LTCRPolicy@hhs.texas.gov or call (512) 438-3161.